Journal for ImmunoTherapy of Cancer: 10 (3)

Basic tumor immunology

Original research: Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer (21 March, 2022)
Tsukasa Masuda, Nobuyuki Tanaka, Kimiharu Takamatsu, Kyohei Hakozaki, Ryohei Takahashi, Tadatsugu Anno, Ryohei Kufukihara, Kazunori Shojo, Shuji Mikami, Toshiaki Shinojima, Kazuhiro Kakimi, Tatsuhiko Tsunoda, Eriko Aimono, Hiroshi Nishihara, Ryuichi Mizuno, Mototsugu Oya
Original research: STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice (17 March, 2022)
Rebekka Bitsch, Annina Kurzay, Feyza Özbay Kurt, Carolina De La Torre, Samantha Lasser, Alisa Lepper, Alina Siebenmorgen, Verena Müller, Peter Altevogt, Jochen Utikal, Viktor Umansky
Original research: TGFβ receptor inhibition unleashes interferon-β production by tumor-associated macrophages and enhances radiotherapy efficacy (17 March, 2022)
Pauline Hamon, Marine Gerbé De Thoré, Marion Classe, Nicolas Signolle, Winchygn Liu, Olivia Bawa, Lydia Meziani, Céline Clémenson, Fabien Milliat, Eric Deutsch, Michele Mondini
IL-1R8 silencing improves the anti-tumor function of freshly isolated human NK cells (15 March, 2022)
Nadine Landolina, Francesca Romana Mariotti, Tiziano Ingegnere, Claudia Alicata, Biancamaria Ricci, Andrea Pelosi, Irene Veneziani, Bruno Giuseppe Azzarone, Cecilia Garlanda, Alberto Mantovani, Lorenzo Moretta, Enrico Maggi
Original research: ZEB1 transcription factor promotes immune escape in melanoma (14 March, 2022)
Maud Plaschka, Valentin Benboubker, Maxime Grimont, Justine Berthet, Laurie Tonon, Jonathan Lopez, Myrtille Le-Bouar, Brigitte Balme, Garance Tondeur, Arnaud de la Fouchardière, Lionel Larue, Alain Puisieux, Yenkel Grinberg-Bleyer, Nathalie Bendriss-Vermare, Bertrand Dubois, Christophe Caux, Stéphane Dalle, Julie Caramel
Original research: Differential role of HLA-A and HLA-B, C expression levels as prognostic markers in colon and rectal cancer (11 March, 2022)
Theodoros Michelakos, Filippos Kontos, Tomohiro Kurokawa, Lei Cai, Ananthan Sadagopan, Danielle Krijgsman, Wilko Weichert, Lindy G Durrant, Peter J K Kuppen, Cristina R Ferrone, Soldano Ferrone
Original research: Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents (10 March, 2022)
Roberta Turiello, Mariaelena Capone, Elva Morretta, Maria Chiara Monti, Gabriele Madonna, Rosa Azzaro, Pasquale Del Gaudio, Ester Simeone, Antonio Sorrentino, Paolo A Ascierto, Silvana Morello
Original research: Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin S (9 March, 2022)
Tom J Harryvan, Marten Visser, Linda de Bruin, Léonie Plug, Lisa Griffioen, Arend Mulder, Peter A van Veelen, Gerbrand J van der Heden van Noort, Marlieke LM Jongsma, Miranda H Meeuwsen, Emmanuel JHJ Wiertz, Saskia J Santegoets, James CH Hardwick, Thorbald Van Hall, Jacques Neefjes, Sjoerd H Van der Burg, Lukas JAC Hawinkels, Els ME Verdegaal
Original research: PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment (9 March, 2022)
Natalie B Collins, Rose Al Abosy, Brian C Miller, Kevin Bi, Qihong Zhao, Michael Quigley, Jeffrey J Ishizuka, Kathleen B Yates, Hans W Pope, Robert T Manguso, Yashaswi Shrestha, Marc Wadsworth, Travis Hughes, Alex K Shalek, Jesse S Boehm, William C Hahn, John G Doench, W Nicholas Haining
Original research:
Necroptosis-driving genes RIPK1, RIPK3 and MLKL-p are associated with intratumoral CD3⁺ and CD8⁺ T cell density and predict prognosis in hepatocellular carcinoma
(9 March, 2022)
Lorenzo Nicolè, Tiziana Sanavia, Rocco Cappellesso, Valeria Maffeis, Jun Akiba, Akihiko Kawahara, Yoshiki Naito, Claudia Maria Radu, Paolo Simioni, Davide Serafin, Giuliana Cortese, Maria Guido, Giacomo Zanus, Hirohisa Yano, Ambrogio Fassina
Original research: System analysis based on the cancer–immunity cycle identifies ZNF207 as a novel immunotherapy target for hepatocellular carcinoma (4 March, 2022)
Xu Wang, Tao Zhou, Xingyi Chen, Yu Wang, Yushi Ding, Haoyang Tu, Shengyang Gao, Haoyu Wang, Xinying Tang, Yong Yang
Original research: Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite (2 March, 2022)
Giorgia Renga, Emilia Nunzi, Marilena Pariano, Matteo Puccetti, Marina Maria Bellet, Giuseppe Pieraccini, Fiorella D’Onofrio, Ilaria Santarelli, Claudia Stincardini, Franco Aversa, Francesca Riuzzi, Cinzia Antognelli, Marco Gargaro, Oxana Bereshchenko, Maurizio Ricci, Stefano Giovagnoli, Luigina Romani, Claudio Costantini

Case reports

Spontaneous tumor regression following COVID-19 vaccination (3 March, 2022)
Luana Guimaraes de Sousa, Daniel J McGrail, Kaiyi Li, Mario L Marques-Piubelli, Cipriano Gonzalez, Hui Dai, Sammy Ferri-Borgogno, Myrna Godoy, Jared Burks, Shiaw-Yih Lin, Diana Bell, Renata Ferrarotto

Clinical/translational cancer immunotherapy

Original research: FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer (31 March, 2022)
Yang Zhang, Fan Huo, Qiang Cao, Ru Jia, Qiju Huang, Zhu A Wang, Dan Theodorescu, Qiang Lv, Pengchao Li, Chao Yan
Original research: Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer (31 March, 2022)
Katy McCann, Adrian von Witzleben, Jaya Thomas, Chuan Wang, Oliver Wood, Divya Singh, Konstantinos Boukas, Kaidre Bendjama, Nathalie Silvestre, Finn Cilius Nielsen, Gareth Thomas, Tilman Sanchez-Elsner, Jason Greenbaum, Stephen Schoenberger, Bjoern Peters, Pandurangan Vijayanand, Natalia Savelyeva, Christian Ottensmeier
Original research: Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy (30 March, 2022)
Megan L Baker, Yu Yamamoto, Mark A Perazella, Nazli Dizman, Anushree C Shirali, Navid Hafez, Jason Weinstein, Michael Simonov, Jeffrey M Testani, Harriet M Kluger, Lloyd G Cantley, Chirag R Parikh, F Perry Wilson, Dennis G Moledina
Original research: Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (25 March, 2022)
Jun Liu, Yang Yang, Zhichao Liu, Xiaolong Fu, Xiaoyue Cai, Hongxuan Li, Li Zhu, Yan Shen, Hong Zhang, Yifeng Sun, Hezhong Chen, Bentong Yu, Renquan Zhang, Jinchen Shao, Ming Zhang, Zhigang Li
Original research: IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer (24 March, 2022)
Timothy A Yap, Alberto Bessudo, Erika Hamilton, Jasgit Sachdev, Manish R Patel, Jordi Rodon, Lena Evilevitch, Meghan Duncan, Wei Guo, Sujatha Kumar, Sharon Lu, Bruce J Dezube, Nashat Gabrail
Original research:
1α,25(OH)₂D₃ reverses exhaustion and enhances antitumor immunity of human cytotoxic T cells
(22 March, 2022)
Peng Li, Xinhai Zhu, Guangchao Cao, Ruan Wu, Ke Li, Wenhui Yuan, Biyun Chen, Guodong Sun, Xichun Xia, Hua Zhang, Xiao Wang, Zhinan Yin, Ligong Lu, Yunfei Gao
Original research: Harnessing radiotherapy-induced NK-cell activity by combining DNA damage–response inhibition and immune checkpoint blockade (21 March, 2022)
Emmanuel C Patin, Magnus T Dillon, Pablo Nenclares, Lorna Grove, Heba Soliman, Isla Leslie, Davina Northcote, Galabina Bozhanova, Eva Crespo-Rodriguez, Holly Baldock, Harriet Whittock, Gabriella Baker, Joan Kyula, Jeane Guevara, Alan A Melcher, James Harper, Hormas Ghadially, Simon Smith, Malin Pedersen, Martin McLaughlin, Kevin J Harrington
Original research: Cancer cell-intrinsic resistance to BiTE therapy is mediated by loss of CD58 costimulation and modulation of the extrinsic apoptotic pathway (16 March, 2022)
Ye Shen, Jason S Eng, Flordeliza Fajardo, Lingming Liang, Cong Li, Patrick Collins, Donato Tedesco, Olivier Nolan-Stevaux
Original research: Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer (16 March, 2022)
Safae Terrisse, Anne-Gaelle Goubet, Kousuke Ueda, Andrew Maltez Thomas, Valentin Quiniou, Cassandra Thelemaque, Garett Dunsmore, Emmanuel Clave, Melissa Gamat-Huber, Satoru Yonekura, Gladys Ferrere, Conrad Rauber, Hang Phuong Pham, Jean-Eudes Fahrner, Eugenie Pizzato, Pierre Ly, Marine Fidelle, Marine Mazzenga, Carolina Alves Costa Silva, Federica Armanini, Federica Pinto, Francesco Asnicar, Romain Daillère, Lisa Derosa, Corentin Richard, Pierre Blanchard, Bertrand Routy, Stéphane Culine, Paule Opolon, Aymeric Silvin, Florent Ginhoux, Antoine Toubert, Nicola Segata, Douglas G McNeel, Karim Fizazi, Guido Kroemer, Laurence Zitvogel
Original research: MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer (15 March, 2022)
Manu Prasad, Jonathan Zorea, Sankar Jagadeeshan, Avital B Shnerb, Sooraj Mathukkada, Jebrane Bouaoud, Lucas Michon, Ofra Novoplansky, Mai Badarni, Limor Cohen, Ksenia M Yegodayev, Sapir Tzadok, Barak Rotblat, Libor Brezina, Andreas Mock, Andy Karabajakian, Jérôme Fayette, Idan Cohen, Tomer Cooks, Irit Allon, Orr Dimitstein, Benzion Joshua, Dexin Kong, Elena Voronov, Maurizio Scaltriti, Yaron Carmi, Cristina Conde-Lopez, Jochen Hess, Ina Kurth, Luc G T Morris, Pierre Saintigny, Moshe Elkabets
The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation (15 March, 2022)
Eva Sum, Moritz Rapp, Harald Dürr, Alekhya Mazumdar, Pedro J Romero, Christine Trumpfheller, Pablo Umaña
Original research: Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer (14 March, 2022)
Stephanie Lheureux, Daniela E Matei, Panagiotis A Konstantinopoulos, Ben X Wang, Ramy Gadalla, Matthew S Block, Andrea Jewell, Stephanie L Gaillard, Michael McHale, Carolyn McCourt, Sarah Temkin, Eugenia Girda, Floor J Backes, Theresa L Werner, Linda Duska, Siobhan Kehoe, Ilaria Colombo, Lisa Wang, Xuan Li, Rachel Wildman, Shirin Soleimani, Scott Lien, John Wright, Trevor Pugh, Pamela S Ohashi, David G Brooks, Gini F Fleming
Original research: Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study (14 March, 2022)
Aung Naing, John D Powderly, John J Nemunaitis, Jason J Luke, Aaron S Mansfield, Wells A Messersmith, Solmaz Sahebjam, Patricia M LoRusso, Ignacio Garrido-Laguna, Lance Leopold, Ryan Geschwindt, Kai Ding, Michael Smith, Jordan D Berlin
Original research: A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL (14 March, 2022)
Naveen K Mehta, Martin Pfluegler, Kristan Meetze, Bochong Li, Isabelle Sindel, Fabian Vogt, Melanie Marklin, Jonas S Heitmann, Joseph Kauer, Lukas Osburg, Latifa Zekri, Hans-Jörg Bühring, Stefanie Mueller, Sebastian Hörner, Patrick A Baeuerle, Jennifer S Michaelson, Gundram Jung, Helmut R Salih
Original research: Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer (14 March, 2022)
Yumeng Wang, Congwen Wang, Junjun Qiu, Xinyu Qu, Jing Peng, Chong Lu, Meng Zhang, Mingxing Zhang, Xingling Qi, Guiling Li, Keqin Hua
Original research: Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) (11 March, 2022)
Douglas G McNeel, Jens C Eickhoff, Ellen Wargowski, Laura E Johnson, Christos E Kyriakopoulos, Hamid Emamekhoo, Joshua M Lang, Mary Jane Brennan, Glenn Liu
Original research: The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling (11 March, 2022)
Max O Meneveau, Pankaj Kumar, Kevin T Lynch, Sapna P Patel, Craig L Slingluff
Original research: CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype (11 March, 2022)
Han Li, Fan Luo, Xingyu Jiang, Weijing Zhang, Tong Xiang, Qiuzhong Pan, Liming Cai, Jingjing Zhao, Desheng Weng, Yue Li, Yuhu Dai, Fengze Sun, Chaopin Yang, Yue Huang, Jieying Yang, Yan Tang, Yulong Han, Mian He, Yanna Zhang, Libing Song, Jian-Chuan Xia
Original research: Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors (9 March, 2022)
Osama E Rahma, Kevin Tyan, Anita Giobbie-Hurder, Andrew S Brohl, Philippe L Bedard, Daniel J Renouf, Elad Sharon, Howard Streicher, Emma Hathaway, Rachel Cunningham, Michael Manos, Mariano Severgnini, Scott Rodig, F Stephen Hodi
Spatial profiling reveals association between WNT pathway activation and T-cell exclusion in acquired resistance of synovial sarcoma to NY-ESO-1 transgenic T-cell therapy (9 March, 2022)
Katie M Campbell, Maneesha Thaker, Egmidio Medina, Anusha Kalbasi, Arun Singh, Antoni Ribas, Theodore Scott Nowicki
Original research: Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint (7 March, 2022)
Zhen-Hua Wu, Na Li, Xiao-Feng Mei, Juan Chen, Xiao-Ze Wang, Ting-Ting Guo, Gang Chen, Lei Nie, Yao Chen, Mei-Zhu Jiang, Ji-Teng Wang, Hai-Bin Wang

Clinical trials monitor

Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study (16 March, 2022)
Haiping Jiang, Xiongfei Yu, Ning Li, Mei Kong, Zhimin Ma, Donghui Zhou, Weibin Wang, Haohao Wang, Haiyong Wang, Kuifeng He, Zhongqi Li, Yimin Lu, Jing Zhang, Kui Zhao, Yafei Zhang, Nong Xu, Ziran Li, Ying Liu, Yan Wang, Yisen Wang, Lisong Teng

Commentaries

Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study (9 March, 2022)
Qi Mei, Guangyuan Hu, Yang Yang, Bo Liu, Junping Yin, Ming Li, Qiao Huang, Xi Tang, Alexander Böhner, Amy Bryant, Christian Kurts, Xianglin Yuan, Jian Li

Immunotherapy biomarkers

Original research: Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis (31 March, 2022)
Xiaofang Xing, Jinyao Shi, Yongning Jia, Yunsheng Dou, Zhongwu Li, Bin Dong, Ting Guo, Xiaojing Cheng, Xiaomei Li, Hong Du, Ying Hu, Shuqin Jia, Jian Zhang, Ziyu Li, Jiafu Ji
Original research: eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma (28 March, 2022)
Xisha Chen, Kuansong Wang, Shilong Jiang, Hongyin Sun, Xuanling Che, Minghui Zhang, Jiaying He, Ying Wen, Mengting Liao, Xiangling Li, Xiaoming Zhou, Jianxun Song, Xingcong Ren, Wenjun Yi, Jinming Yang, Xiang Chen, Mingzhu Yin, Yan Cheng
Original research: DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma (25 March, 2022)
Angelika Martina Starzer, Gerwin Heller, Erwin Tomasich, Thomas Melchardt, Katharina Feldmann, Teresa Hatziioannou, Stefan Traint, Christoph Minichsdorfer, Ursula Schwarz-Nemec, Maja Nackenhorst, Leonhard Müllauer, Matthias Preusser, Anna Sophie Berghoff, Thorsten Fuereder
Original research: Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer (25 March, 2022)
Yijia Xu, Han Zeng, Kaifeng Jin, Zhaopei Liu, Yu Zhu, Le Xu, Zewei Wang, Yuan Chang, Jiejie Xu
Original research: Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma (18 March, 2022)
Robert J Motzer, Toni K Choueiri, David F McDermott, Thomas Powles, Yann-Alexandre Vano, Saurabh Gupta, Jin Yao, Celine Han, Ron Ammar, Simon Papillon-Cavanagh, Shruti S Saggi, M Brent McHenry, Petra Ross-Macdonald, Megan Wind-Rotolo
C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer (15 March, 2022)
Niklas Klümper, Jonas Saal, Fiamma Berner, Christa Lichtensteiger, Nina Wyss, Annkristin Heine, Franz Georg Bauernfeind, Jörg Ellinger, Peter Brossart, Stefan Diem, Sabine Schmid, Markus Joerger, Martin Frueh, Manuel Ritter, Michael Hölzel, Lukas Flatz, Tobias Bald
Original research: MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer (11 March, 2022)
Julie Lecuelle, Laure Favier, Cléa Fraisse, Aurélie Lagrange, Coureche Kaderbhai, Romain Boidot, Sandy Chevrier, Philippe Joubert, Bertrand Routy, Caroline Truntzer, Francois Ghiringhelli
Original research: Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors (8 March, 2022)
Xiaozhen Zhang, Mengyi Lao, Jian Xu, Yi Duan, Hanshen Yang, Muchun Li, Honggang Ying, Lihong He, Kang Sun, Chengxiang Guo, Wen Chen, Haitao Jiang, Xiaoyu Zhang, Xueli Bai, Tingbo Liang
Original research: Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab (7 March, 2022)
Khalid Jazieh, Mohammadhadi Khorrami, Anas Saad, Mohamed Gad, Amit Gupta, Pradnya Patil, Vidya Sankar Viswanathan, Prabhakar Rajiah, Charles J Nock, Michael Gilkey, Pingfu Fu, Nathan A Pennell, Anant Madabhushi
Original research: In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies (4 March, 2022)
Caterina Ieranò, Dario Righelli, Crescenzo D'Alterio, Maria Napolitano, Luigi Portella, Giuseppina Rea, Federica Auletta, Sara Santagata, Anna Maria Trotta, Giuseppe Guardascione, Federica Liotti, Nella Prevete, Piera Maiolino, Antonio Luciano, Antonio Barbieri, Annabella Di Mauro, Cristin Roma, Riziero Esposito Abate, Fabiana Tatangelo, Roberto Pacelli, Nicola Normanno, Rosa Marina Melillo, Stefania Scala
Original research: Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer (3 March, 2022)
Yuezong Bai, Tong Xie, Zhenghang Wang, Shuang Tong, Xiaochen Zhao, Feilong Zhao, Jinping Cai, Xiaofan Wei, Zhi Peng, Lin Shen
Original research: Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies (2 March, 2022)
Javier Glez-Vaz, Arantza Azpilikueta, Irene Olivera, Assunta Cirella, Alvaro Teijeira, Maria C Ochoa, Maite Alvarez, Iñaki Eguren-Santamaria, Carlos Luri-Rey, Maria E Rodriguez-Ruiz, Xinxin Nie, Lieping Chen, Sonia Guedan, Miguel F Sanmamed, Jose Luis Perez Gracia, Ignacio Melero

Immune cell therapies and immune cell engineering

Original research: Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy (25 March, 2022)
Xin Liu, Yixiang Xu, Wei Xiong, Bingnan Yin, Yuqian Huang, Junjun Chu, Changsheng Xing, Chen Qian, Yang Du, Tianhao Duan, Helen Y Wang, Ningyan Zhang, John S. Yu, Zhiqiang An, Rongfu Wang
Original research: T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion (14 March, 2022)
Laura T Morton, Tassilo L A Wachsmann, Miranda H Meeuwsen, Anne K Wouters, Dennis F G Remst, Marleen M van Loenen, J H Frederik Falkenburg, Mirjam H M Heemskerk
Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy (9 March, 2022)
Kristin G Anderson, Shannon K Oda, Breanna M Bates, Madison G Burnett, Magdalia Rodgers Suarez, Susan L Ruskin, Philip D Greenberg
Generalizable design parameters for soluble T cell receptor-based T cell engagers (8 March, 2022)
Karen J Froning, Arlene Sereno, Flora Huang, Stephen J Demarest

Oncolytic and local immunotherapy

Original research: Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression (31 March, 2022)
Bin-Jin Hwang, Li-Chung Tsao, Chaitanya R Acharya, Timothy Trotter, Pankaj Agarwal, Junping Wei, Tao Wang, Xiao-Yi Yang, Gangjun Lei, Takuya Osada, Herbert Kim Lyerly, Michael A Morse, Zachary Conrad Hartman
Original research: CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma (25 March, 2022)
Galabina Bozhanova, Jehanne Hassan, Lizzie Appleton, Victoria Jennings, Shane Foo, Martin McLaughlin, Charleen ML Chan Wah Hak, Emmanuel C Patin, Eva Crespo-Rodriguez, Gabby Baker, Edward Armstrong, Matthew Chiu, Hardev Pandha, Adel Samson, Victoria Roulstone, Joan Kyula, Richard Vile, Fiona Errington-Mais, Malin Pedersen, Kevin Harrington, Masahiro Ono, Alan Melcher
Original research: Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors (25 March, 2022)
Rocio Garcia-Carbonero, Miriam Bazan-Peregrino, Marta Gil-Martín, Rafael Álvarez, Teresa Macarulla, Maria C Riesco-Martinez, Helena Verdaguer, Carmen Guillén-Ponce, Martí Farrera-Sal, Rafael Moreno, Ana Mato-Berciano, Maria Victoria Maliandi, Silvia Torres-Manjon, Marcel Costa, Natalia del Pozo, Jaime Martínez de Villarreal, Francisco X Real, Noemí Vidal, Gabriel Capella, Ramon Alemany, Emma Blasi, Carmen Blasco, Manel Cascalló, Ramon Salazar
Original research: Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer (16 March, 2022)
Jacob P van Vloten, Kathy Matuszewska, Mark A A Minow, Jessica A Minott, Lisa A Santry, Madison Pereira, Ashley A Stegelmeier, Thomas M McAusland, Elaine M Klafuric, Khalil Karimi, Joseph Colasanti, D Grant McFadden, James J Petrik, Byram W Bridle, Sarah K Wootton
Original research: Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis (14 March, 2022)
Tianyu Tang, Xing Huang, Gang Zhang, Minghao Lu, Zhengtao Hong, Meng Wang, Junming Huang, Xiao Zhi, Tingbo Liang
Original research:
PI3Kδ/γ inhibitor BR101801 extrinsically potentiates effector CD8⁺ T cell-dependent antitumor immunity and abscopal effect after local irradiation
(14 March, 2022)
Yi Na Yoon, Eunju Lee, Young-Ju Kwon, Jeong-An Gim, Tae-Jin Kim, Jae-Sung Kim
Original research: Neoadjuvant in situ vaccination with cowpea mosaic virus as a novel therapy against canine inflammatory mammary cancer (11 March, 2022)
Daniel Alonso-Miguel, Guillermo Valdivia, Diego Guerrera, Maria Dolores Perez-Alenza, Stanislav Pantelyushin, Angela Alonso-Diez, Veronique Beiss, Steven Fiering, Nicole F Steinmetz, Maria Suarez-Redondo, Johannes vom Berg, Laura Peña, Hugo Arias-Pulido
Original research: Immunotherapy combining tumor and endothelium cell lysis with immune enforcement by recombinant MIP-3α Newcastle disease virus in a vessel-targeting liposome enhances antitumor immunity (7 March, 2022)
Jin-Yan Wang, Hengyu Chen, Shu-Zhen Dai, Feng-Ying Huang, Ying-Ying Lin, Cai-Chun Wang, Lei Li, Wu-Ping Zheng, Guang-Hong Tan
Original research: Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression (4 March, 2022)
Adam Nelson, Simon Gebremeskel, Brian D Lichty, Brent Johnston
Original research: Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy (2 March, 2022)
Jianjun Hu, Jiangyi He, Yunlong Wang, Yang Zhao, Kejing Fang, Yan Dong, Yanrong Chen, Yue Zhang, Chi Zhang, Hongwei Wang, Jun Tan, Junyi Wang, Ruiyang Zi, Chengxiang Liu, Houjie Liang, Yanli Guo, Juanjuan Ou

Position article and guidelines

Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis (16 March, 2022)
Christopher Ma, Rish K Pai, David F Schaeffer, Jonathan Krell, Leonardo Guizzetti, Stefanie C McFarlane, John K MacDonald, Won-Tak Choi, Roger M Feakins, Richard Kirsch, Gregory Y Lauwers, Reetesh K Pai, Christophe Rosty, Amitabh Srivastava, Joanna C. Walsh, Brian G Feagan, Vipul Jairath

Review

Role of mass spectrometry-based serum proteomics signatures in predicting clinical outcomes and toxicity in patients with cancer treated with immunotherapy (28 March, 2022)
Yeonggyeong Park, Min Jeong Kim, Yoonhee Choi, Na Hyun Kim, Leeseul Kim, Seung Pyo Daniel Hong, Hyung-Gyo Cho, Emma Yu, Young Kwang Chae

Main menu

Table of contents

March 2022 - Volume 10 - 3

Basic tumor immunology

Case reports

Clinical/translational cancer immunotherapy

Clinical trials monitor

Commentaries

Immunotherapy biomarkers

Immune cell therapies and immune cell engineering

Oncolytic and local immunotherapy

Position article and guidelines

Review

Corrections

Log in using your username and password

Main menu

Log in using your username and password

You are here

Table of contents

March 2022 - Volume 10 - 3

Basic tumor immunology

Case reports

Clinical/translational cancer immunotherapy

Clinical trials monitor

Commentaries

Immunotherapy biomarkers

Immune cell therapies and immune cell engineering

Oncolytic and local immunotherapy

Position article and guidelines

Review

Corrections